Efficacy and safety of Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) versus Bortezomib, Melphalan, and Prednisone (VMP) in Chinese patients with newly diagnosed Multiple Myeloma: OCTANS

被引：0

作者：

Fu, Weijun ^{[1
]}

Huang, Honghui ^{[2
]}

Li, Wei ^{[3
]}

An, Gang ^{[4
]}

Cai, Zhen ^{[5
]}

Jin, Jie ^{[5
]}

Wang, Yafei ^{[6
]}

Chim, Chor Sang ^{[7
]}

Qi, Ming ^{[8
]}

Wang, Jianping ^{[9
]}

Song, Yang ^{[10
]}

Jia, Bin ^{[11
]}

Yang, Xue ^{[11
]}

Liu, Wenyu ^{[10
]}

Li, Yunan ^{[12
]}

Zhang, Renyi ^{[13
]}

Hou, Jian ^{[14
]}

Wang, Jianxiang ^{[4
]}

机构：

[1] Shanghai Changzheng Hosp, Shanghai, Peoples R China

[2] Shanghai Jiao Tong Univ, Renji Hosp, Dept Hematol, Sch Med, Shanghai, Peoples R China

[3] First Hosp Jilin Univ, Dept Hematol, Oncol Ctr, Changchun, Peoples R China

[4] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China

[5] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China

[6] Tianjin Canc Hosp, Tianjin, Peoples R China

[7] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China

[8] Janssen Res & Dev LLC, Spring House, PA USA

[9] Janssen Res & Dev LLC, Raritan, NJ USA

[10] Janssen Res & Dev LLC, Beijing, Peoples R China

[11] Janssen Res & Dev LLC, Shanghai, Peoples R China

[12] Xian Janssen Pharmaceut Ltd, Med Affairs, Beijing, Peoples R China

[13] Xian Janssen Pharmaceut Ltd, Med Affairs, Shanghai, Peoples R China

[14] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Hematol, Shanghai, Peoples R China

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-163

引用

页码：S125 / S125

页数：1

共 50 条

[11] Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM)
Facon, Thierry
Lee, Jae Hoon
Moreau, Philippe
Niesvizky, Ruben
Dimopoulos, Meletios Athanasios
Hajek, Roman
Osman, Muhtarjan
Aggarwal, Sanjay
Klippel, Zandra
Miguel, Jesus San
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E26 - E27
[12] Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study
Fu, Weijun
Bang, Soo-Mee
Huang, Honghui
Kim, Kihyun
Li, Wei
An, Gang
Lee, Je-Jung
Cai, Zhen
Jin, Jie
Wang, Yafei
Chim, Chor Sang
Carson, Robin
Liu, Rui
Zhao, Man
Chen, Xi
Cui, Canchan
Hou, Jian
Wang, Jianxiang
ANNALS OF HEMATOLOGY, 2025, 104 (01) : 515 - 525
[13] Bortezomib-Melphalan-Prednisone (VMP) Versus MP as Initial Treatment for Very Elderly Patients With Newly Diagnosed Multiple Myeloma
Kim, Min Kyoung
Kim, Kihyun
Yoon, Do Hyun
Suh, Cheolwon
Moon, Joon Ho
Lee, Yoo Jin
Lee, Jae Hoon
Jung, Sung-Hoon
Lee, Je-Jung
Kim, Hyo Jung
Bae, Sung Hwa
Kim, Jin Seok
Lee, Jeong-Ok
Eom, Hyeon Seok
Lee, Won-Sik
Kang, Hye Jin
Mun, Yeung-Chul
Do, Young Rok
Hyun, Myung Soo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E70 - E70
[14] Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone
Mateos, Maria-Victoria
Cavo, Michele
Blade, Joan
Dimopoulos, Meletios A.
Suzuki, Kenshi
Jakubowiak, Andrzej
Knop, Stefan
Doyen, Chantal
Lucio, Paulo
Nagy, Zsolt
Pour, Ludek
Cook, Mark
Grosicki, Sebastian
Crepaldi, Andre H.
Liberati, Anna Marina
Campbell, Philip
Shelekhova, Tatiana
Yoon, Sung-Soo
Iosava, Genadi
Fujisaki, Tomoaki
Garg, Mamta
Krevvata, Maria
Wang, Jianping
Kudva, Anupa
Ukropec, Jon
Wroblewski, Susan
Kobos, Rachel
San-Miguel, Jesus
BLOOD, 2019, 134
[15] Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients
Palumbo, Antonio
Bringhen, Sara
Rossi, Dmide
Cavalli, Maide
Ria, Roberto
Gentilini, Silvia
Patriarca, Francesca
Nozzoli, Chiara
Levi, Anna
Guglielmelli, Tommasina
Benevolo, Giulia
Vincelli, Donatella
Baldini, Luca
Morabito, Fortunato
Grasso, Mariella
Marasca, Roberto
Rizzo, Manuela
Pautasso, Chiara
Falcone, Antonietta Pia
Gottardi, Daniela
Montefusco, Vittorio
Musolino, Caterina
Cangialosi, Clotilde
Mansueto, Giovanna
Liberati, Anna Marina
Magarotto, Valeria
Omede, Paola
Musto, Pellegrino
Petrucci, Maria Teresa
Boccadoro, Mario
BLOOD, 2012, 120 (21)
[16] Prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) for newly diagnosed elderly myeloma
Renaud, Loic
Leleu, Xavier
HEMATOLOGIE, 2014, 20 (03): : 138 - 138
[17] Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies
Cavo, Michele
Dimopoulos, Meletios A.
San-Miguel, Jesus
Mateos, Maria-Victoria
Jakubowiak, Andrzej
Deraedt, William
Lam, Annette
Kampfenkel, Tobias
Qi, Ming
He, Jianming
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (07): : 480 - 489
[18] Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
Mateos, Maria-Victoria
Dimopoulos, Meletios A.
Cavo, Michele
Suzuki, Kenshi
Knop, Stefan
Doyen, Chantal
Lucio, Paulo
Nagy, Zsolt
Pour, Ludek
Grosicki, Sebastian
Crepaldi, Andre
Liberati, Anna Marina
Campbell, Philip
Yoon, Sung-Soo
Iosava, Genadi
Fujisaki, Tomoaki
Garg, Mamta
Iida, Shinsuke
Blade, Joan
Ukropec, Jon
Pei, Huiling
Van Rampelbergh, Rian
Kudva, Anupa
Qi, Ming
San-Miguel, Jesus
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 785 - 798
[19] Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment
Morabito, Fortunato
Gentile, Massimo
Mazzone, Carla
Rossi, Davide
Di Raimondo, Francesco
Bringhen, Sara
Ria, Roberto
Offidani, Massimo
Patriarca, Francesca
Nozzoli, Chiara
Petrucci, Maria Teresa
Benevolo, Giulia
Vincelli, Iolanda
Guglielmelli, Tommasina
Grasso, Mariella
Marasca, Roberto
Baldini, Luca
Montefusco, Vittorio
Musto, Pellegrino
Cascavilla, Nicola
Majolino, Ignazio
Musolino, Caterina
Cavo, Michele
Boccadoro, Mario
Palumbo, Antonio
BLOOD, 2011, 118 (22) : 5759 - 5766
[20] Cost-effectiveness analysis of daratumumab plus bortezomib, melphalan and prednisone versus bortezomib, melphalan and prednisone in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation
Xie, Dan
Zhang, Peng-Fei
BMJ OPEN, 2025, 15 (02):

← 1 2 3 4 5 →